Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. (LCTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lctx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Lineage Cell Therapeutics, Inc. (LCTX) measures how much investors pay for each dollar of the company's trailing earnings. LCTX's current PE ratio of N/A is calculated by dividing its stock price of $1.22 by its TTM earnings per share of -$0.26.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Lineage Cell Therapeutics, Inc.You LCTX | $303M | N/A | — | -$0.26 |
 ADC Therapeutics S.A. ADCT | $114M | N/A | — | -$1.12 |
 Autolus Therapeutics plc AUTL | $387M | N/A | — | -$1.08 |
 Benitec Biopharma Inc. BNTC | $275M | N/A | — | -$1.05 |
 Fulcrum Therapeutics, Inc. FULC | $189M | N/A | — | -$1.18 |
 Galectin Therapeutics Inc. GALT | $157M | N/A | — | -$0.48 |
 Neurogene Inc. NGNE | $415M | N/A | — | -$4.27 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.28 | — | |
2024-12-31 FY2024 | — | $-0.09 | — | |
2023-12-31 FY2023 | — | $-0.12 | — | |
2022-12-31 FY2022 | — | $-0.15 | — | |
2021-12-31 FY2021 | — | $-0.26 | — | |
2020-12-31 FY2020 | — | $-0.14 | — | |
2019-12-31 FY2019 | — | $-0.08 | — | |
2018-12-31 FY2018 | — | $-0.36 | — | |
2017-12-31 FY2017 | — | $-0.17 | — | |
2016-12-31 FY2016 | 10.46x | $0.34 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Lineage Cell Therapeutics, Inc. (LCTX) measures how much investors pay for each dollar of the company's trailing earnings. LCTX's current PE ratio of N/A is calculated by dividing its stock price of $1.22 by its TTM earnings per share of -$0.26.
Frequently asked questions
LCTX pe ratio · 6 questionsLCTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.22 and TTM EPS of -$0.26. Data sourced from Financial Modeling Prep via LCTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Lineage Cell Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08